PARP1 and cancer: Human cancer cells use both proteasome‐dependent and proteasome‐independent endonucleolytic pathways (TDP1, PARP1, XPF‐ERCC1, MRE11, CTIP, and MUS81‐EM1) to remove TOP1cc (Tomicic & Kaina, 2013).